Amgen Inc. (BCBA:AMGN)
Argentina · Delayed Price · Currency is ARS | Market Cap | 388.50T +67.1% |
| Revenue (ttm) | 56.44T +9.1% |
| Net Income | 12.95T +32.1% |
| EPS | 829.00 +31.6% |
| Shares Out | n/a |
| PE Ratio | 30.98 |
| Forward PE | 19.62 |
| Dividend | 362.74 (1.41%) |
| Ex-Dividend Date | Nov 20, 2026 |
| Volume | 9,503 |
| Open | 26,020 |
| Previous Close | 25,800 |
| Day's Range | 25,440 - 26,020 |
| 52-Week Range | 14,380 - 26,260 |
| Beta | 0.41 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About Amgen
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2025, Amgen's revenue was $36.75 billion, an increase of 9.95% compared to the previous year's $33.42 billion. Earnings were $7.71 billion, an increase of 88.53%.
Financial numbers in USD Financial StatementsNews
AMGEN ANNOUNCES WEBCAST OF 2026 THIRD QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif., Oct. 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2026 financial results on Tuesday, November 3, 2026, after the close of t...
Amgen says video ad for Vectibix cited by FDA never publicly disseminated
As previously reported, in a letter to Amgen (AMGN) Chairman and CEO, the FDA said: “The Office of Prescription Drug Promotion of the U.S. Food and Drug Administration has reviewed…
Amgen to present results from Phase 3 OASIZ-301 study at ACR
Amgen (AMGN) will present late-breaking results from the Phase 3 OASIZ-301 study evaluating dazodalibep in adults living with Sjogren’s disease and moderate-to-severe systemic disease activity. Dazoda...
AMGEN TO PRESENT NEW DATA ACROSS RARE AND OTHER SERIOUS AUTOIMMUNE DISEASES AT ACR CONVERGENCE 2026
Phase 3 OASIZ-301 Study of Dazodalibep in Sjögren's Disease Shows Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity and Patient-Reported Dryness New Long-Ter...
Amgen names David Gibbs to board of directors
Amgen (AMGN) announced the appointment of David Gibbs to its Board of Directors, effective immediately. Gibbs will serve on the Board’s Audit Committee and Compensation and Management Development Comm...
AMGEN APPOINTS DAVID W. GIBBS TO BOARD OF DIRECTORS
THOUSAND OAKS, Calif., Oct. 26, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the appointment of David W.
Amgen announces Phase 3 results of Imdelltra with AstraZeneca’s Imfinzi
Amgen (AMGN) announced an interim Phase 3 results showing that Imdelltra in combination with AstraZeneca’s (AZN) Imfinzi reduced the risk of death by 58% as a first-line maintenance treatment for…
Amgen Transcript: 2026 European Society for Medical Oncology (ESMO) Annual Congress
DeLLphi-305 showed significant OS and PFS benefits for IMDELLTRA plus IMFINZI in first-line maintenance, with responses across subgroups and manageable reported toxicities. Development is advancing into earlier SCLC settings, while monitoring and dosing initiatives aim to widen access.
Amgen Slides: FY 2026
Amgen has posted slides in relation to its FY 2026 quarterly earnings report, which was published on October 24, 2026.
Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
A drug from Amgen could give patients with a notoriously aggressive form of lung cancer significantly more time to live when added to an immunotherapy from AstraZeneca. Full results from a late-stage...
IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
Nearly 80% of Patients Were Alive at One Year Versus 53% with IMFINZI Alone and Progression-Free Survival More Than Tripled Late-Breaking Phase 3 DeLLphi-305 Results Presented in ESMO Presidential Sy...
Amgen price target raised to $480 from $450 at Oppenheimer
Oppenheimer analyst Jay Olson raised the firm’s price target on Amgen (AMGN) to $480 from $450 and keeps an Outperform rating on the shares ahead of quarterly results. The firm…
Amgen price target raised to $400 from $380 at Barclays
Barclays raised the firm’s price target on Amgen (AMGN) to $400 from $380 and keeps an Equal Weight rating on the shares as part of a Q3 earnings preview. The…
AMGEN TO PRESENT AT THE EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS 2026
THOUSAND OAKS, Calif., Oct. 20, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society of Medical Oncology Congress (ES...
AstraZeneca reports full results from Phase 3 CROSSING trial of Tezspire
Full results from the “positive” Phase 3 CROSSING trial showed that AstraZeneca (AZN) and Amgen’s (AMGN) Tezspire demonstrated statistically significant and clinically meaningful improvements in the c...
AstraZeneca, Amgen announce TEZSPIRE showed ‘significant’ improvements
Full results from the Phase III CROSSING trial showed that AstraZeneca (AZN) and Amgen’s (AMGN) TEZSPIRE demonstrated statistically significant and clinically meaningful improvements in the co-primary...
AstraZeneca-Amgen asthma drug hits 69% remission in esophageal disease trial
Amgen and AstraZeneca said on Tuesday their asthma drug helped reduce swallowing difficulties and achieved disease remission in 69% of patients with a type of chronic inflammatory disorder of the es...
TEZSPIRE® DELIVERED HISTOLOGIC REMISSION AND SYMPTOM IMPROVEMENT IN EOSINOPHILIC ESOPHAGITIS
Symptom Improvements Versus Placebo at Week 24 Were Sustained Through Week 52 Statistically Significant Total Endoscopic Remission with No Visible Inflammation or Fibrosis Attained Versus Placebo at W...
Amgen price target lowered to $378 from $388 at Guggenheim
Guggenheim analyst Vamil Divan lowered the firm’s price target on Amgen (AMGN) to $378 from $388 and keeps a Neutral rating on the shares as the firm updated its model…
Amgen price target lowered to $415 from $450 at BMO Capital
BMO Capital lowered the firm’s price target on Amgen (AMGN) to $415 from $450 and keeps a Market Perform rating on the shares as part of a broader research note…
Amgen price target raised to $328 from $317 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Amgen (AMGN) to $328 from $317 and keeps an Underperform rating on the shares after updating estimates ahead of the…
Amgen price target lowered to $430 from $435 at Wells Fargo
Wells Fargo lowered the firm’s price target on Amgen (AMGN) to $430 from $435 following pipeline valuation updates, while keeping an Equal Weight rating on the shares. The firm expects…
Amgen price target raised to $470 from $430 at UBS
UBS raised the firm’s price target on Amgen (AMGN) to $470 from $430 and keeps a Buy rating on the shares. The firm previewed Q3 earnings for the U.S. pharma…